Pregnolia System Intra-observer Variability
Launched by PREGNOLIA AG · Jan 6, 2022
Trial Information
Current as of June 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Informed Consent signed by the subject
- • Pregnant woman
- • Singleton pregnancy
- • 18 years or older
- • Nulliparous cohort: nulliparous pregnant woman
- • Multiparous cohort: multiparous pregnant woman
- Exclusion Criteria:
- • Lack of informed consent
- • Placenta praevia totalis with haemorrhage (irrespective of severity)
- • Severe vaginal bleeding
- • Rupture of membranes before 34 weeks (to be excluded with pH test)
- • Visible tissue scarring at 12 o'clock position on cervix
- • Light bleeding (if the bleeding can be stopped, it is no longer an exclusion criterion)
- • Cervical dilation ≥ 3 cm
- • Cerclage or pessary in place
About Pregnolia Ag
Pregnolia AG is an innovative clinical trial sponsor focused on advancing women's health, particularly in the areas of pregnancy and reproductive medicine. With a commitment to developing cutting-edge solutions, Pregnolia AG leverages its expertise in medical technology and clinical research to address critical challenges in maternal and fetal health. The company aims to enhance clinical outcomes through the development of novel diagnostic and therapeutic approaches, ensuring the safety and well-being of both mothers and their children. By collaborating with leading healthcare professionals and institutions, Pregnolia AG strives to contribute significantly to the field of obstetrics and gynecology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Frauenfeld, , Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials